Get the Stockscreener App
34.50
2.38%
-0.899
Crinetics Pharmaceuticals Inc stock is traded at $34.50, with a volume of 86,611.
It is down -2.38% in the last 24 hours and down -1.99% over the past month.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
See More
Previous Close:
$35.40
Open:
$35.35
24h Volume:
86,611
Relative Volume:
0.10
Market Cap:
$3.26B
Revenue:
$4.72M
Net Income/Loss:
$-277.91M
P/E Ratio:
-9.2496
EPS:
-3.73
Net Cash Flow:
$-203.56M
1W Performance:
+1.31%
1M Performance:
-1.99%
6M Performance:
-35.77%
1Y Performance:
-14.67%
1-Day Range:
$34.52
$36.00
1-Week Range:
$32.62
$36.00
52-Week Range:
$31.84
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA
Compare CRNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
34.60 | 3.26B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
498.54 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
678.02 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.05 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.79 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.47 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | TD Cowen | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Peer Perform |
| Jan-22-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Jan-16-24 | Initiated | Morgan Stanley | Overweight |
| Dec-21-23 | Initiated | Jefferies | Hold |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-31-23 | Initiated | Oppenheimer | Outperform |
| Apr-24-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Robert W. Baird | Outperform |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-23-21 | Initiated | Evercore ISI | Outperform |
| Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-23-19 | Initiated | ROTH Capital | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Aug-13-18 | Initiated | JP Morgan | Neutral |
| Aug-13-18 | Initiated | Leerink Partners | Outperform |
| Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Will Crinetics Pharma's Upcoming Events Drive Stock Momentum? - RTTNews
Bank of New York Mellon Corp Has $17.63 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
Crinetics Pharmaceuticals Grants Stock Options and RSUs to New Employees Under 2021 Inducement Plan - Nasdaq
Crinetics Awards Major Stock Grants to 17 New Hires Including Executive - StockTitan
Proficio Capital Partners LLC Acquires Shares of 14,674 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Promising Pipeline and Strategic Initiatives Drive Buy Rating for Crinetics Pharmaceuticals - TipRanks
Principal Financial Group Inc. Boosts Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharma’s Earnings Call: Progress Amid Challenges - TipRanks
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2024 Earnings Call Transcript - MSN
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Up 6.1% on Better-Than-Expected Earnings - Defense World
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance UK
Cantor Fitzgerald lifts Crinetics stock target to $100 By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals (NASDAQ:CRNX) Reaches New 1-Year LowHere's What Happened - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Announces Earnings Results - MarketBeat
Crinetics Pharmaceuticals: Promising Developments and Strategic Initiatives Underpin Buy Rating - TipRanks
Crinetics price target lowered to $91 from $92 at Citizens JMP - TipRanks
Crinetics Pharmaceuticals: Promising Future with Paltusotine Launch and Robust Pipeline Development - TipRanks
Crinetics Pharmaceuticals: Positioned for Growth with Promising Drug Pipeline and Strong Financials - TipRanks
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Crinetics Pharmaceuticals: Financial Results and Future Plans - TipRanks
Crinetics Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Crinetics Pharmaceuticals Q4 Net Loss Narrows -February 27, 2025 at 05:15 pm EST - Marketscreener.com
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Is Crinetics Pharmaceuticals (CRNX) the Worst Performing Mid Cap Stock to Buy According to Analysts? - Insider Monkey
Investors push Crinetics Pharmaceuticals (NASDAQ:CRNX) 11% lower this week, company's increasing losses might be to blame - Simply Wall St
CRNX stock touches 52-week low at $35.47 amid market shifts - MSN
New York State Common Retirement Fund Grows Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Rhumbline Advisers Increases Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
What To Expect From Crinetics Pharmaceuticals Inc (CRNX) Q4 2024 Earnings - GuruFocus.com
Venturi Wealth Management LLC Invests $41,000 in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals appoints Tobin Schilke as CFO - MSN
Crinetics Pharmaceuticals (CRNX) Expected to Announce Earnings on Thursday - Defense World
State of New Jersey Common Pension Fund D Increases Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
After leaving FDA, Cavazzoni joins Pfizer as CMO - BioCentury
Crinetics Pharmaceuticals is Now Oversold (CRNX) - Nasdaq
First Week of April 17th Options Trading For Crinetics Pharmaceuticals (CRNX) - Nasdaq
Crinetics Pharmaceuticals Appoints New Chief Financial Officer - TipRanks
Crinetics Pharmaceuticals Names Tobin Schilke CFO -February 24, 2025 at 09:10 am EST - Marketscreener.com
Crinetics Pharmaceuticals Hires CFO from Revance - MarketWatch
Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer - The Manila Times
Can This Biotech CFO's $1.5B Deal Experience Transform Crinetics' Commercial Future? - StockTitan
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences - The Manila Times
Can Crinetics Reveal New Strategic Insights at Major March Healthcare Conferences? - StockTitan
Objective long/short (CRNX) Report - Stock Traders Daily
Crinetics Pharmaceuticals (CRNX) Expected to Announce Earnings on Wednesday - MarketBeat
TD Cowen initiates Crinetics stock with Buy rating, sees high potential - MSN
Rep. Gilbert Ray Cisneros, Jr. Buys Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 12-Month LowWhat's Next? - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Coverage Initiated at TD Cowen - MarketBeat
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Crinetics Pharmaceuticals Inc Stock (CRNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pizzuti Dana | Chief Med and Dev Officer |
Feb 03 '25 |
Sale |
39.07 |
5,000 |
195,350 |
31,748 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):